By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that a combination of its Imfinzi immunotherapy with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.
The London-listed pharmaceutical company said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive at three years.
The company said that the combination--known as the STRIDE regimen--also showed no increase in severe liver toxicity and that no bleeding risk was observed.
Separately, AstraZeneca said Imfinzi plus chemotherapy reduced the risk of death by 20% in first-line advanced biliary tract cancer when compared with chemotherapy on its own.
"Positive results from the Topaz-1 Phase III trial showed AstraZeneca's Imfinzi, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer," the company said.
Write to Anthony O. Goriainoff at firstname.lastname@example.org
(END) Dow Jones Newswires